Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| STXS - Stereotaxis | 13.30% | Hold | 13,680,554 | $3.73 | $51M | — | — |
| XBI - Spdr Sp Biotech ETF | 6.31% | New | 269,500 | $89.88 | $24M | +269,500 | +$24M |
| FATE - Fate Therapeutics | 5.06% | Add +34.6% | 500,930 | $38.77 | $19M | +128,770 | −$2M |
| Blueprint Medicines | 4.10% | Add +19.0% | 246,280 | $63.88 | $16M | +39,369 | −$6M |
| Adicet Bio | 3.73% | Reduce −2.4% | 715,872 | $19.97 | $14M | −17,300 | +$1M |
| NDAQ - Nasdaq Omx | 3.48% | Add +150.6% | 102,500 | $130.30 | $13M | +61,600 | +$7M |
| XENE - Xenon Pharmaceuticals | 3.03% | Reduce −5.6% | 380,163 | $30.57 | $12M | −22,504 | −$957K |
| Karuna Therapeutics | 2.71% | Add +13.3% | 82,053 | $126.78 | $10M | +9,630 | +$916K |
| DXCM - Dexcom | 2.42% | Hold | 18,138 | $511.58 | $9M | — | — |
| BHVN - Biohaven | 2.40% | Add +33.6% | 77,600 | $118.57 | $9M | +19,500 | +$1M |
| NBIX - Neurocrine Biosciences | 2.04% | Hold | 83,655 | $93.75 | $8M | — | — |
| CYTK - Cytokinetics | 2.03% | Add +57.7% | 211,495 | $36.81 | $8M | +77,401 | +$2M |
| NRIX - Nurix Therapeutics | 1.98% | Add +77.4% | 543,344 | $14.01 | $8M | +237,024 | −$1M |
| Morphic | 1.90% | Hold | 181,467 | $40.15 | $7M | — | — |
| Cardiovascular Sys | 1.69% | Hold | 286,988 | $22.60 | $6M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.68% | Add +25.4% | 371,987 | $17.38 | $6M | +75,452 | −$26K |
| Merus | 1.62% | Add +3.9% | 234,989 | $26.44 | $6M | +8,900 | −$977K |
| Sage Therapeutics | 1.56% | Hold | 180,306 | $33.10 | $6M | — | — |
| RVMD - Revolution Medicines | 1.54% | Add +9.4% | 232,101 | $25.51 | $6M | +19,870 | +$579K |
| IDYA - Ideaya Biosciences | 1.43% | Add +6.5% | 490,061 | $11.19 | $5M | +30,000 | −$5M |
| Cymabay Therapeutics | 1.37% | Reduce −5.3% | 1,692,569 | $3.11 | $5M | −95,000 | −$778K |
| Iveric Bio | 1.31% | Add +8.2% | 298,476 | $16.83 | $5M | +22,500 | +$409K |
| Natus Medical | 1.31% | Hold | 190,635 | $26.28 | $5M | — | — |
| APLSUSD - Apellis Pharmaceuticals | 1.24% | New | 93,935 | $50.81 | $5M | +93,935 | +$5M |
| ATRC - Atricure | 1.23% | Hold | 72,029 | $65.67 | $5M | — | — |
| RCUS - Arcus Biosciences | 1.19% | Add +23.9% | 145,217 | $31.56 | $5M | +28,017 | −$160K |
| ALEC - Alector | 1.09% | Add +88.6% | 292,747 | $14.25 | $4M | +137,500 | +$966K |
| Otonomy | 0.94% | Reduce −31.9% | 1,497,514 | $2.40 | $4M | −702,783 | −$983K |
| ASND - Ascendis Pharma A/S | 0.94% | Add +178.3% | 30,612 | $117.37 | $4M | +19,612 | +$2M |
| Mirati Therapeutics | 0.91% | New | 42,700 | $82.22 | $4M | +42,700 | +$4M |
| EWTX - Edgewise Therapeutics | 0.90% | New | 356,750 | $9.70 | $3M | +356,750 | +$3M |
| IPSC - Century Therapeutics | 0.84% | Add +156.5% | 256,892 | $12.59 | $3M | +156,757 | +$2M |
| ARAY - Accuray | 0.81% | Hold | 941,800 | $3.31 | $3M | — | — |
| Pardes Biosciences | 0.79% | Add +80.4% | 421,157 | $7.22 | $3M | +187,657 | −$781K |
| TCOM - Field Trip Health | 0.77% | Add +542.8% | 2,191,308 | $1.34 | $3M | +1,850,408 | +$2M |
| Iteos Therapeutics | 0.75% | Add +65.1% | 89,298 | $32.18 | $3M | +35,208 | +$356K |
| Kalvista Pharmaceuticals | 0.73% | Hold | 190,663 | $14.74 | $3M | — | — |
| Rigel Pharmaceuticals | 0.70% | Add +1.9% | 896,100 | $2.99 | $3M | +17,100 | +$350K |
| LKFT - Galapagos | 0.69% | Hold | 42,675 | $62.03 | $3M | — | — |
| AXGN - Axogen | 0.69% | Hold | 332,103 | $7.94 | $3M | — | — |
| Aerie Pharmaceuticals | 0.69% | Hold | 289,040 | $9.10 | $3M | — | — |
| Affimed | 0.65% | Hold | 571,282 | $4.37 | $2M | — | — |
| F-Star Therapeutics | 0.64% | Hold | 693,785 | $3.55 | $2M | — | — |
| BCYC - Bicycle Therapeutics | 0.61% | New | 53,200 | $43.87 | $2M | +53,200 | +$2M |
| Athira Pharma | 0.57% | Hold | 160,983 | $13.50 | $2M | — | — |
| AUTL - Autolus Therapeutics | 0.54% | New | 496,150 | $4.17 | $2M | +496,150 | +$2M |
| Surface Oncology | 0.52% | Add +115.9% | 680,000 | $2.94 | $2M | +365,000 | +$493K |
| KURA - Kura Oncology | 0.47% | Add +2.3% | 113,329 | $16.08 | $2M | +2,500 | +$270K |
| Dice Therapeutics | 0.47% | New | 94,000 | $19.13 | $2M | +94,000 | +$2M |
| BWAY - Brainsway | 0.45% | Hold | 200,000 | $8.73 | $2M | — | — |
| BMEA - Biomea Fusion | 0.45% | Add +22.3% | 383,923 | $4.46 | $2M | +70,000 | −$627K |
| Radius Health | 0.44% | Hold | 191,978 | $8.83 | $2M | — | — |
| Macrogenics | 0.44% | Add +113.3% | 192,000 | $8.81 | $2M | +102,000 | +$247K |
| COGT - Cogent Biosciences | 0.44% | Hold | 223,554 | $7.49 | $2M | — | — |
| Kinnate Biopharma | 0.43% | Add +39.2% | 148,151 | $11.26 | $2M | +41,698 | −$218K |
| Regulus Therapeutics | 0.43% | Hold | 5,555,555 | $0.2981 | $2M | — | — |
| Ngm Biopharmaceuticals | 0.43% | Add +33.8% | 107,653 | $15.25 | $2M | +27,168 | +$217K |
| Immunocore | 0.42% | New | 53,878 | $29.90 | $2M | +53,878 | +$2M |
| Holding | 0.42% | Add +28.0% | 59,452 | $26.85 | $2M | +13,000 | −$620K |
| Mersana Therapeutics | 0.37% | Add +151.5% | 352,763 | $3.99 | $1M | +212,500 | +$536K |
| Venus Concept | 0.36% | Reduce −0.8% | 968,187 | $1.43 | $1M | −7,500 | −$274K |
| Mereo Biopharma Group | 0.36% | Add +8.0% | 1,216,613 | $1.12 | $1M | +90,000 | −$440K |
| VKTX - Viking Therapeutics | 0.35% | Hold | 447,400 | $3.00 | $1M | — | — |
| 89BIO | 0.32% | Add +124.0% | 324,053 | $3.77 | $1M | +179,400 | −$669K |
| Mei Pharma | 0.28% | Add +0.1% | 1,767,146 | $0.6027 | $1M | +2,300 | −$4M |
| Gh Research | 0.26% | New | 55,000 | $18.29 | $1M | +55,000 | +$1M |
| CMPS - Compass Pathways | 0.25% | New | 74,890 | $12.89 | $965K | +74,890 | +$965K |
| Neuronetics | 0.25% | Hold | 313,717 | $3.03 | $951K | — | — |
| Theseus Pharmaceuticals | 0.24% | Reduce −17.8% | 80,124 | $11.53 | $924K | −17,376 | −$312K |
| Nextcure | 0.24% | Hold | 187,696 | $4.86 | $912K | — | — |
| BDTX — | 0.23% | Add +52.2% | 313,600 | $2.77 | $869K | +107,500 | −$230K |
| WVE - Wave Life Sciences | 0.20% | Hold | 390,161 | $2.00 | $780K | — | — |
| Genfit S A | 0.20% | Add +210.9% | 187,940 | $4.00 | $752K | +127,492 | +$450K |
| Adaptimmune Therapeutics | 0.19% | Add +157.6% | 351,064 | $2.06 | $723K | +214,798 | +$212K |
| Vigil Neuroscience | 0.18% | New | 99,754 | $7.03 | $701K | +99,754 | +$701K |
| Sutro Biopharma | 0.18% | Add +88.2% | 84,700 | $8.22 | $696K | +39,700 | +$26K |
| PHVS - Pharvaris | 0.16% | Reduce −5.7% | 34,615 | $18.14 | $628K | −2,105 | +$100K |
| Lava Therapeutics | 0.16% | Hold | 139,332 | $4.40 | $613K | — | — |
| Harpoon Therapeutics | 0.14% | Hold | 105,163 | $4.97 | $523K | — | — |
| Phasebio Pharmaceuticals | 0.13% | Hold | 378,611 | $1.32 | $500K | — | — |
| INGN - Inogen | 0.13% | Hold | 15,000 | $32.40 | $486K | — | — |
| SCYXEUR - Scynexis | 0.12% | Hold | 121,242 | $3.91 | $474K | — | — |
| Masimo | 0.11% | Hold | 3,000 | $145.67 | $437K | — | — |
| Compugen | 0.11% | Reduce −35.4% | 130,202 | $3.22 | $419K | −71,300 | −$447K |
| MDGL - Madrigal Pharmaceuticals | 0.08% | Reduce −44.6% | 3,100 | $98.06 | $304K | −2,500 | −$171K |
| CMPX - Compass Therapeutics | 0.07% | Hold | 196,091 | $1.37 | $269K | — | — |
| Aslan Pharmaceuticals | 0.06% | Reduce −66.7% | 243,720 | $0.8986 | $219K | −488,780 | −$601K |
| Holding | 0.06% | Add +75.0% | 140,000 | $1.54 | $216K | +60,000 | +$20K |
| LRMR - Larimar Therapeutics | 0.05% | Reduce −28.8% | 49,996 | $4.04 | $202K | −20,181 | −$555K |
| Surgalign | 0.05% | Hold | 579,710 | $0.3036 | $176K | — | — |
| Infinity Pharmaceuticals | 0.04% | Reduce −49.1% | 120,097 | $1.14 | $137K | −116,063 | −$394K |
| ANNX - Annexon | 0.02% | Hold | 30,796 | $2.73 | $84K | — | — |
Showing top 50 of 92 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Arena Pharmaceuticals | 2.80% | Exit | 0 | $92.94 | $11M | −119,615 | −$11M |
| Hookipa Pharma | 0.19% | Exit | 0 | $2.33 | $747K | −320,444 | −$747K |
| PRQR - Proqr Therapeutics | 0.17% | Exit | 0 | $8.01 | $685K | −85,476 | −$685K |
| Bolt Biotherapeutics | 0.12% | Exit | 0 | $4.90 | $490K | −100,000 | −$490K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2